menu search

BDSI / BioDelivery's stock rockets toward a 2-year high after buyout deal with Collegium at a 54% premium

BioDelivery's stock rockets toward a 2-year high after buyout deal with Collegium at a 54% premium
Shares of BioDelivery Sciences International Inc. BDSI, -1.62% blasted 51.7% higher to pace all premarket gainers Monday, after the specialty pharmaceutical company with a portfolio of pain and neurology products agreed to be acquired by Collegium Pharmaceutical Inc. COLL, -0.23% in a deal valued at about $604 million. Collegium's stock was still inactive ahead of the open. Read More
Posted: Feb 14 2022, 07:00
Author Name: Market Watch
Views: 111938

BDSI News  

Has BioDelivery Sciences International (BDSI) Outpaced Other Medical Stocks This Year?

By Zacks Investment Research
March 18, 2022

Has BioDelivery Sciences International (BDSI) Outpaced Other Medical Stocks This Year?

Here is how BioDelivery Sciences International (BDSI) and Vertex Pharmaceuticals (VRTX) have performed compared to their sector so far this year. more_horizontal

Earnings Preview: BioDelivery Sciences International (BDSI) Q4 Earnings Expected to Decline

By Zacks Investment Research
March 2, 2022

Earnings Preview: BioDelivery Sciences International (BDSI) Q4 Earnings Expected to Decline

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared wi more_horizontal

Earnings Preview: BioDelivery Sciences International (BDSI) Q4 Earnings Expected to Decline

By Zacks Investment Research
March 2, 2022

Earnings Preview: BioDelivery Sciences International (BDSI) Q4 Earnings Expected to Decline

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared wi more_horizontal

Earnings Preview: BioDelivery Sciences International (BDSI) Q4 Earnings Expected to Decline

By Zacks Investment Research
March 2, 2022

Earnings Preview: BioDelivery Sciences International (BDSI) Q4 Earnings Expected to Decline

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared wi more_horizontal

BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium

By Zacks Investment Research
February 15, 2022

BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium

Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of more_horizontal

BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium

By Zacks Investment Research
February 15, 2022

BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium

Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of more_horizontal

BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium

By Zacks Investment Research
February 15, 2022

BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium

Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of more_horizontal

BDSI Stock Alert: The Deal Sending Little-Known BioDelivery Skyrocketing Today

By InvestorPlace
February 14, 2022

BDSI Stock Alert: The Deal Sending Little-Known BioDelivery Skyrocketing Today

Today, a big takeover announcement has sent shares of BioDelivery and BDSI stock soaring more than 50% on investor enthusiasm for this deal. The post more_horizontal


Search within

Pages Search Results: